Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
As part of the deal, AstraZeneca is acquiring the exclusive rights to ECC5004, an investigational oral once-daily pill for treating obesity, type 2 diabetes and other cardiometabolic conditions
You may download the form, complete it and email back to [email protected]
Although we provide detailed written and video tutorials on how to self-inject, you can visit LJCSC for weekly onsite injections administered by our medical pros if that makes you more comfortable
Escalating symptoms despite standard management may require protocol modification
to treat chronic obesity
Insurance Coverage Differs Widely Across Options Some alternatives like Contrave or phentermine-topiramate carry lower out-of-pocket costs and broader insurance approval compared to newer GLP-1 or GIP drugs
US$ 29.74
US$ 27.88
US$ 20.84
US$ 23.08
US$ 20.96
US$ 25.76
US$ 26.35
US$ 23.34
US$ 27.59
